New antibiotic development for pulmonary infections: New Drugs for Bad Bugs and beyond

Tomislav Kostyanev, Marc J.M. Bonten, Herman Goossens

Source: Eur Respir Monogr 2017; 75: 289-301
Disease area: Respiratory infections

Congress or journal article abstractFull text journal article

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Tomislav Kostyanev, Marc J.M. Bonten, Herman Goossens. New antibiotic development for pulmonary infections: New Drugs for Bad Bugs and beyond. Eur Respir Monogr 2017; 75: 289-301

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.

Related content which might interest you:
Management of drug resistant pulmonary TB. New problems and perspectives
Source: Annual Congress 2009 - Multi/extensively-drug resistant tuberculosis
Year: 2009

New and repurposed drugs
Source: Eur Respir Monogr 2018; 82: 179-204
Year: 2018

Management of COVID-19: Drugs anti-virals
Source: ERS Course 2021 - COVID-19: State of the art
Year: 2021

New technologies of corrections hemithorax in treatment of pulmonary tuberculosis
Source: International Congress 2016 – Open problems in thoracic surgery
Year: 2016

New horizons in ventilator development
Source: ERS Course 2018 - Noninvasive ventilation: advanced
Year: 2018

Research in respiratory medicine: New approaches in genetic diseases
Source: ERS Summit on priorities in respiratory medicine 2011
Year: 2011

New Drugs for COPD: the current status
Source: Research Seminar 2014 - Human translational medicine: a key bridge for the development of new drugs for severe asthma, COPD and ILD
Year: 2014

New anti-tuberculosis drugs for special populations: a difficult-to-address issue
Source: Eur Respir J 2016; 48: 957-958
Year: 2016

New frontiers in the management of asthma
Source: International Congress 2017 – State of the art session: "Paediatric"
Year: 2017

Prospects for new compounds tiosemikarbazonami class to create drugs with antituberculosis activity
Source: International Congress 2014 – Tuberculosis: diagnosis
Year: 2014

New targets for drug development in asthma
Source: Annual Congress 2008 - A step-change in asthma. The Lancet/ERS symposium
Year: 2008

New and repurposed drugs for MDR-TB patients
Source: International Congress 2017 – PG2 Multidrug-resistant tuberculosis management in settings with a low tuberculosis incidence 
Year: 2017

Phenotypes of symptomatic airways disease in China and New Zealand
Source: Eur Respir J, 50 (6) 1700957; 10.1183/13993003.00957-2017
Year: 2017

New definition of pulmonary rehabilitation
Source: Annual Congress 2012 - The updated ATS/ERS statement on pulmonary rehabilitation - update from the ATS/ERS Task Force
Year: 2012

New horizons in bronchiectasis
Source: International Congress 2017 – Bronchiectasis: from guidelines to real life
Year: 2017